Benign Prostatic Hyperplasia

Mallhi, Tauqeer Hussain; Ijaz, Erum; Butt, Muhammad Hammad; Khan, Yusra Habib; Shah, Shahid; Rehman, Kanwal; Salman, Muhammad; Ullah, Faiz; Raja, Ahsan Aftab; Khan, Amjad; Khan, Tahir Mehmood

doi:10.1007/978-3-030-74786-2_87-1

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding complexity to this landscape is the diversity of clinical outcomes observed in BPH patients with prostatic inflammation (13,14). Studies have reported varying degrees of symptom severity, response to standard pharmacotherapy, and progression to acute urinary retention or the need for surgical intervention among these individuals (15,16).…”

Section: Introductionmentioning

confidence: 99%

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Mehmood,

Ayaz,

Kakakhel

2024

JHRR

View full text Add to dashboard Cite

Background: Benign prostate hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, prevalently impacts the aging male population, often disrupting the quality of life with its accompanying urinary symptoms. The intersection between BPH and prostatic inflammation has emerged as a focal point in urological research, with inflammation speculated to exacerbate BPH progression and symptoms. Understanding this relationship is pivotal in refining therapeutic approaches and improving patient outcomes. Objective: This study aimed to elucidate the effects of prostatic inflammation on the clinical outcomes of patients with BPH, focusing on symptom progression, treatment efficacy, and long-term complications. Methods: This Study Conducted at Gajju Khan Medical College Swabi, KPK, Pakistan, in the duration from January, 2023 to June, 2023. This prospective cohort study involved 126 men with BPH, categorized into two groups based on the presence (n=63) or absence (n=63) of prostatic inflammation. Data were collected over three years, with assessments including demographic information, clinical histories, and prostate examinations. Primary outcomes measured were the progression of BPH symptoms, urinary function, and prostate size. Secondary outcomes included quality of life, acute urinary retention, the need for surgical intervention, medication efficacy, and long-term complications. Statistical analyses employed included Chi-square tests, t-tests, and ANOVA, with SPSS software. Results: The group with prostatic inflammation showed significantly more severe symptom progression (p < 0.01), impaired urinary function (p < 0.01), and increased prostate size (p < 0.01) compared to the non-inflamed group. Secondary outcomes also favored the non-inflamed group with better quality of life scores (75.2 ± 5.2 vs. 78.8 ± 4.8, p < 0.01), lower rates of acute urinary retention (20.3% vs. 15.5%, p < 0.01). Conclusion: Prostatic inflammation significantly worsens the clinical outcomes of BPH, affecting symptom progression, treatment response, and the likelihood of long-term complications. These findings suggest the need for integrated therapeutic strategies that address both BPH and prostatic inflammation to optimize patient care.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Mehmood,

Ayaz,

Kakakhel

2024

JHRR

View full text Add to dashboard Cite

show abstract

“…Benign prostatic hyperplasia (BPH) is an age-related medical condition in which the prostate gland enlarges (1). BPH usually causes bladder tract obstruction, produces lower urinary tract symptoms, decreases the quality of life, and increases health costs.…”

Section: Introductionmentioning

confidence: 99%

Gestational exposure to the great Chinese famine: early life undernutrition impact on prostatic hyperplasia in adulthood

Wang,

Zhang,

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

IntroductionBenign prostatic hyperplasia (BPH) is a frequent illness in aged men that impacts their quality of life; early childhood exposure to famines may have long-term effects on the chance of developing BPH. The aim of this study is to investigate the relationship between early-life famine exposure and benign prostatic hyperplasia (BPH) risk in Chinese men born during 1959–1961.MethodsWe used medical records from a large, comprehensive hospital to screen people born in China during the years of famine (1959–1961). Birthplaces were identified as indicators of famine exposure status. In the time window between 2017 and 2022, people born during the famine years who had prostatic ultrasonic examinations were selected, and their medical records were retrieved from the database. Univariate and multivariate logistic regression analyses investigated the relationship between famine exposure and BPH risk.ResultsA total of 3,009 subjects were included in this study. Patients with heavy famine exposure had older age, shorter height, lighter weight, lower cholesterol, lower uric acid (UA), lower aspartate aminotransferase (ALT), and a higher incidence of BPH than those with light famine exposure (all p < 0.05). Univariate logistic regression showed that BPH was positively related to famine exposure, age, height, weight, and body mass index (BMI) but negatively related to UA (all p < 0.05). Multivariate logistic regression showed that age and famine exposure were still independent risk factors (p < 0.05), while UA was an independent protective factor for BPH (p < 0.05). Heavy famine exposure increased the risk of BPH (adjusted OR = 1.214, 95% CI = 1.05–1.467, p = 0.045).Conclusions and recommendationFamine and malnutrition exposure during early life may be independent risk factors for BPH in Chinese adults. This relationship provides additional evidence to support the fetal origins of adult diseases and offers clues for the pathological mechanisms of BPH.

show abstract

α1-adrenoceptor antagonists and 5α-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia

Dight

2024

Journal of Paramedic Practice

View full text Add to dashboard Cite

Benign prostatic hyperplasia is a condition that develops in the majority of men and is by some estimates is the most prevalent of all minor ailments. A healthily functioning prostate is important for the workings of the male reproductive and urinary systems. The most frequently prescribed first-line pharmacological treatments for lower urinary tract symptoms attributed to benign prostatic hyperplasia are α1-adrenoceptor antagonists and 5α-reductase inhibitors; surgery can also be carried out. Expert consensus and a strong body of evidence show these drugs are safe and effective. However, they come with a variety of side-effects so patients' priorities and iifestyles will influence pharmacological management.

show abstract

Benign Prostatic Hyperplasia

Cited by 3 publications

References 39 publications

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Gestational exposure to the great Chinese famine: early life undernutrition impact on prostatic hyperplasia in adulthood

α1-adrenoceptor antagonists and 5α-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia

Contact Info

Product

Resources

About